Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Last trade$19.91
Day change-$1.50 (-7.01%)
Day range$19.75 – $21.58
Volume1,336,642
Market cap$2.03B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.03B
Price / earnings
—
Price / book
9.91×
Price / sales
—
EV / sales
—
EV / EBITDA
-6.97×
Profitability
Earnings per share
-$2.86
Return on assets
-72.48%
Return on equity
-132.36%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.61×
Current ratio
7.11×
Quick ratio
6.9×
Cash ratio
6.76×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$245.77M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for REPL, quarterly periods
Line item
Q2 FY2027 Sep 30, 2026
Q1 FY2027 Jun 30, 2026
Q4 FY2026 Mar 31, 2026
Q3 FY2026 Dec 31, 2025
Q2 FY2026 Sep 30, 2025
Q1 FY2026 Jun 30, 2025
Q4 FY2025 Mar 31, 2025
Q3 FY2025 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$21.92M
$18.97M
$21.01M
$18.73M
$26.41M
$32.58M
$25.35M
$18.02M
Research and development
$34.37M
$49.28M
$52.32M
$53.14M
$57.88M
$57.84M
$53.98M
$48M
Total operating expenses
$56.28M
$68.25M
$73.34M
$71.87M
$84.29M
$90.42M
$79.33M
$66.02M
Operating income
-$56.28M
-$68.25M
-$73.34M
-$71.87M
-$84.29M
-$90.42M
-$79.33M
-$66.02M
Interest expense
-$3.03M
-$3.09M
-$2.88M
-$1.98M
-$2.01M
-$2M
-$1.99M
-$1.98M
Income before taxes
-$57.12M
-$69.77M
-$73.46M
-$71.24M
-$83.1M
-$86.69M
-$74.24M
-$65.77M
Income taxes
$0
$0
-$240K
-$311K
$0
$0
-$107K
$575K
Net income
-$57.12M
-$69.77M
-$73.22M
-$70.93M
-$83.1M
-$86.69M
-$74.13M
-$66.34M
Net income attributable to common shareholders
-$57.12M
-$69.77M
-$73.22M
-$70.93M
-$83.1M
-$86.69M
-$74.13M
-$66.34M
EBITDA
-$55.51M
-$67.31M
-$72.57M
-$69.31M
-$83.45M
-$89.55M
-$78.48M
-$63.37M
Basic earnings per share
-$0.54
-$0.72
-$0.77
-$0.77
-$0.90
-$0.95
-$0.81
-$0.79
Diluted earnings per share
-$0.54
-$0.72
-$0.77
-$0.77
-$0.90
-$0.95
-$0.81
-$0.79
Recent news
Company coverage with links to the original publishers.
Replimune's stock surged 80% over the past month following FDA accelerated approval and commercial launch of Tudriqev (RP1) in combination with Bristol Myers' Opdivo for treating unresectable advanced cutaneous melanoma. Early adoption at leading melanoma centers and better-than-expected Q2 2027 earnings results drove investor confidence. The company's pipeline candidate RP2 is advancing in multiple cancer indications with preliminary results expected in Q1 2027.
Replimune Group (REPL) has gained 34.7% over the past four weeks and closed at $17.61. Wall Street analysts have a mean price target of $22.33, suggesting a potential 26.8% upside. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions with a 7.7% increase over the last 30 days. However, the article cautions that price targets alone should not be the sole basis for investment decisions.
Replimune successfully launched TUDRIQEV, its first commercial therapy for advanced melanoma, achieving rapid adoption with over 15 medical centers writing prescriptions within 20 business days. The company's in-house manufacturing facility provides over one year of ready inventory with next-day delivery capability nationwide. With $307.8 million in cash reserves, Replimune is well-positioned to fund operations and clinical studies for over 12 months, supported by major payer coverage and NCCN guideline listing.
Mestag Therapeutics announced the appointment of Philip Astley-Sparke and Victor Sandor, M.D.C.M. to its Board of Directors. Both appointees bring extensive biotech and oncology development experience. The appointments strengthen the Board as Mestag advances MST-0312, a targeted lymphotoxin-beta agonist bispecific antibody, in the Phase 1 STARLYS trial for patients with advanced solid tumors.
A class action lawsuit has been filed against Replimune Group Inc. for allegedly making materially false statements regarding its Biologics License Application (BLA). The lawsuit claims the company failed to disclose that FDA study design concerns were not addressed and that submitted data from an early analysis included only 40 of 400 planned patients, likely causing FDA rejection of the BLA. Investors who purchased securities between October 20, 2025 and April 10, 2026 can apply to be lead plaintiff by October 5, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.